AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Next-Generation KRAS Inhibitors in NSCLC: A Pipeline So Active It's Hard to Keep Up
By Robert Chun-Hao Hsu, MD
KRAS was considered undruggable for decades. The protein's smooth, shallow surface offered no obvious pocket for small molecule binding. Its extremely high affinity for GTP/GDP made competitive inhibition impractical.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving
By Deepti Behl, MD
Platinum-etoposide served as the cornerstone of therapy, producing rapid responses that were often followed by equally rapid relapses, and few effective subsequent options.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.
Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor
By The Cancer News Team
To illustrate what a 20% survival rate looks like in practice, Force opens with a case: a 10-year-old boy brought to a rural East African hospital by his grandmother with a progressive jaw mass, intermittent fevers, and microcytic anemia.